Across TCGA pan-cancer cohorts, OR4C46 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR4C46 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR4C46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4C46 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

LIHC, UCEC, and COAD are the cancer types where OR4C46 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.051	0.783	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.623	.021	18	view →
COAD	OS	Median	III,IV	0.161	0.783	.006	15	view →
LGG	DFS	Median	All	0.132	0.832	<.001	6	view →
LUSC	DFS	Median	All	0.937	0.750	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: OR4C46 tumor-vs-normal RNA expression · all OR4C46 data types